Physician profile
Corbin Ballam
NPI 1205282894
$2,460.46
in general payments reported to CMS, 2019-2025
31 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.47 · 2020: $29.15 · 2021: $51.56 · 2022: $123 · 2023: $597 · 2024: $1,211 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $282.51 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $192.22 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $174.98 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Penumbra, INC. | $170.85 | 2025 | Indigo System |
| Teva Pharmaceuticals USA, INC. | $127.75 | 2022-2024 | Austedo Xr |
| Glaxosmithkline, LLC. | $127.56 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $125.27 | 2023-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $112.14 | 2023-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $100.96 | 2023-2024 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $94.76 | 2024-2025 | |
| Pfizer INC. | $88.28 | 2023-2024 | |
| Lilly USA, LLC | $84.12 | 2019-2024 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $81.13 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $80.01 | 2024-2025 | Gemtesa |
| Almatica Pharma LLC | $79.34 | 2023-2025 | Loreev Xr, Teriparatide |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $72.60 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $63.38 | 2024 | Voquezna |
| Novo Nordisk INC | $59.74 | 2024-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.47 | 2024 | Jardiance |
| Aimmune Therapeutics, INC. | $37.66 | 2024 | |
| Idorsia Pharmaceuticals US INC | $36.14 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.46 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $35.15 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Radius Health, INC. | $29.15 | 2020 | |
| Medtronic, INC. | $23.51 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.50 | 2024 | Gvoke Hypopen |
| Amarin Pharma, INC. | $18.49 | 2019 | |
| Eisai INC. | $18.09 | 2024 | |
| Paratek Pharmaceuticals, INC. | $17.86 | 2023 | Nuzyra |
| Nestle Healthcare Nutrition INC. | $13.35 | 2023 | |
| Boston Scientific Corporation | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corbin Ballam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.